Health and Fitness Health and Fitness
Thu, July 7, 2011
Wed, July 6, 2011
[ Wed, Jul 06th 2011 ] - Market Wire
Larry Renfro Named CEO of Optum
Tue, July 5, 2011
Mon, July 4, 2011
Sat, July 2, 2011
Fri, July 1, 2011
Thu, June 30, 2011
[ Thu, Jun 30th 2011 ] - Market Wire
KCI???NPWT????????????
Wed, June 29, 2011
Tue, June 28, 2011
Mon, June 27, 2011
Sat, June 25, 2011
Fri, June 24, 2011
Thu, June 23, 2011
Wed, June 22, 2011
Tue, June 21, 2011
Mon, June 20, 2011
Sun, June 19, 2011
Fri, June 17, 2011
Thu, June 16, 2011
Wed, June 15, 2011
Tue, June 14, 2011
[ Tue, Jun 14th 2011 ] - Market Wire
Bond Labs Reports May Results
Mon, June 13, 2011
Fri, June 10, 2011

Immunovaccine Announces Results of 2011 AGM


//health-fitness.news-articles.net/content/2011/ .. immunovaccine-announces-results-of-2011-agm.html
Published in Health and Fitness on Thursday, June 23rd 2011 at 5:50 GMT by Market Wire   Print publication without navigation


HALIFAX, June 23, 2011 /CNW/ - Immunovaccine Inc. (TSX-V: IMV) (the "Company" or "Immunovaccine"), a clinical stage vaccine developer, today announced the results of the Company's annual general meeting of shareholders (AGM) held on June 22, 2011.

At the AGM, the shareholders elected Brad Thompson, Ph.D., and Kimberly Stephens, C.A., as new directors and re-elected: Dr. William A. Cochrane, Wade K. Dawe, James W. Hall and Albert Scardino to serve on the Board of Directors until the next annual meeting of shareholders. Albert Scardino will also assume the duties of the non-executive Chair of the Board. Former directors Michael Kirby and Paul Kirkconnell did not stand for re-election.

"The Board and management wish to thank Mr. Kirby and Mr. Kirkconnell for their service and contributions to the Board," said Albert Scardino, Chair of Immunovaccine.

The shareholders approved all motions put forth at the meeting including the appointment of PricewaterhouseCoopers LLP, Chartered Accountants, as the Company's independent auditors.

Immunovaccine Inc. is focused on the commercialization of its patented DepoVax™ vaccine delivery platform and product candidates. Currently, the Company has developed two therapeutic cancer vaccine candidates for clinical trials. With the goal of developing premium therapeutic cancer and infectious disease vaccines, Immunovaccine continues to strengthen its vaccine pipeline through licensing and strategic partnerships with companies worldwide. [ www.imvaccine.com ]

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information.  Forward-looking statements are based on the estimates and opinions of management on the date the statements are made.  However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release. 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Publication Contributing Sources